Michelle McMurry-Heath washed overboard at BIO as industry group wrestles over its future, hunts new CEO
In the end, the internal tensions ripping at BIO had barely surfaced in fresh turmoil then the stormy surface waters were smoothed by CEO Michelle McMurry-Heath’s quick exit. Late Monday came word that she had resigned from her top post, swapping it for an advisory position, and soon after we learned that longtime biotech exec Rachel King would be taking her position until they can find a full-time replacement.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.